Cargando…

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer

PURPOSE: Gemcitabine (GEM)-based chemotherapy has been used worldwide as the first-line treatment for advanced biliary tract cancer (BTC). However, no standard regimens have been established yet for patients with GEM-refractory BTC. A previous phase II trial of S-1 as a first-line treatment in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Eiichiro, Ikeda, Masafumi, Okusaka, Takuji, Nakamori, Shoji, Ohkawa, Shinichi, Nagakawa, Tatsuya, Boku, Narikazu, Yanagimoto, Hiroaki, Sato, Tosiya, Furuse, Junji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3636435/ https://www.ncbi.nlm.nih.gov/pubmed/23525694 http://dx.doi.org/10.1007/s00280-013-2106-0

Ejemplares similares

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Okusaka, Takuji, et al.
Publicado: (2015)

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
por: Ioka, Tatsuya, et al.
Publicado: (2015)

Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017)

Targeted Therapy for Biliary Tract Cancer
por: Furuse, Junji, et al.
Publicado: (2011)

Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial
por: Furuse, Junji, et al.
Publicado: (2022)

Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

nal‐IRI+5‐FU/LV versus 5‐FU/LV in post‐gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
por: Ueno, Makoto, et al.
Publicado: (2020)

Early Relapse of Unresectable Gallbladder Cancer after Discontinuation of Gemcitabine Monotherapy Administered for 5 Years in a Patient Who Had Complete Response to the Treatment
por: Suyama, Koichi, et al.
Publicado: (2013)

Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer
por: Ueno, Makoto, et al.
Publicado: (2019)

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis
por: Furuse, Junji, et al.
Publicado: (2017)

Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
por: Yamaguchi, Tomohiro, et al.
Publicado: (2014)

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer(†)
por: Ueno, M., et al.
Publicado: (2016)

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
por: Okusaka, T, et al.
Publicado: (2010)

A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
por: Ueno, Makoto, et al.
Publicado: (2017)

Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
por: Sakamoto, Yasunari, et al.
Publicado: (2019)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ohkawa, S, et al.
Publicado: (2015)

Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
por: Okusaka, Takuji, et al.
Publicado: (2020)

Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data
por: Hamada, Chikuma, et al.
Publicado: (2017)

Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113
por: Ueno, Makoto, et al.
Publicado: (2021)

Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study
por: Ueno, Makoto, et al.
Publicado: (2021)

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
por: Yamaue, Hiroki, et al.
Publicado: (2015)

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial
por: Morizane, Chigusa, et al.
Publicado: (2022)

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)

Immunotherapy for hepatocellular carcinoma: current status and future perspectives
por: Okusaka, Takuji, et al.
Publicado: (2018)

Everolimus for Advanced Pancreatic Neuroendocrine Tumours: A Subgroup Analysis Evaluating Japanese Patients in the RADIANT-3 Trial
por: Ito, Tetsuhide, et al.
Publicado: (2012)

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
por: Okusaka, Takuji, et al.
Publicado: (2015)

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer
por: Matsuyama, Masato, et al.
Publicado: (2014)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)
por: Toyoda, Masanori, et al.
Publicado: (2014)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

A Phase I study of pevonedistat plus capecitabine plus oxaliplatin in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
por: Shoji, Hirokazu, et al.
Publicado: (2021)

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ioka, T, et al.
Publicado: (2017)

Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis
por: Okusaka, Takuji, et al.
Publicado: (2020)

A pathological complete response after combined chemotherapy of gemcitabine and S-1 in advanced biliary tract cancer with para-aortic lymph nodes metastasis: a case report
por: Watanabe, Takeshi, et al.
Publicado: (2017)

Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world
por: Kaku, Sawako, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6tsu0brt60p5772vrlkrj7eqqo